Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 135086106 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Dani Reiss
13G/A
Amendment 8
|
22.3% |
9/24/2026
Event 9/9/2026
|
|
| Dani Reiss | 22.3% | ||
| DTR LLC | 20.7% | ||
|
WBT Value Ltd
13G
|
11.8% |
9/8/2026
Event 9/7/2026
|
|
| WBT Value Ltd | 11.8% | ||
| Lucky Season Limited | 11.8% | ||
| Lucky Season Trust | 11.8% | ||
| Jiezhong Luo | 11.8% | ||
|
WBT Value Ltd
13G
|
10.0% |
6/11/2026
Event 6/10/2026
|
|
| WBT Value Limited | 10.0% | ||
| Lucky Season Limited | 10.0% | ||
| Lucky Season Trust | 10.0% | ||
| Zheyu Huang | 10.0% | ||
| Ilex Capital Partners (UK) LLP 13G | 4.1% |
5/14/2026
Event 3/31/2026
|
|
|
Fortune Enrichment Holdings Ltd
13G
|
8.4% |
3/20/2026
Event 3/20/2026
|
|
| Fortune Enrichment Holdings Limited | 8.4% | ||
| Lucky Season Limited | 8.4% | ||
| Lucky Season Trust | 8.4% | ||
| Zheyu Huang | 8.4% | ||
|
FMR LLC
13G/A
Amendment 8
|
10.8% |
3/6/2026
Event 2/27/2026
|
|
| FMR LLC | 10.8% | ||
| Abigail P. Johnson | 10.8% | ||
|
Bain Capital Integral Investors 2008, L.P.
13G/A
Amendment 6
|
40.1% |
2/17/2026
Event 12/31/2025
|
|
| Bain Capital Integral Investors 2008, L.P. | 40.1% | ||
| BCPE Fund X Goose Holdings, L.P. | 0% | ||
| Ilex Capital Partners (UK) LLP 13G | 5.4% |
2/11/2026
Event 12/31/2025
|
|
|
Portolan Capital Management, LLC
13G
|
6.3% |
1/16/2026
Event 1/9/2026
|
|
| Portolan Capital Management, LLC | 6.3% | ||
| George McCabe | 6.3% | ||
|
Morgan Stanley
13G/A
Amendment 7
|
0% |
1/8/2026
Event 12/31/2025
|
|
| Morgan Stanley | 0% | ||
| Morgan Stanley Investment Management Inc. | 0% | ||
| Morgan Stanley Institutional Fund, Inc. - International Advantage Portfolio | 0% | ||
|
Ameriprise Financial, Inc.
13G/A
Amendment 5
|
3.8% |
11/14/2025
Event 9/30/2025
|
|
| Ameriprise Financial, Inc. | 3.8% | ||
| Ameriprise Financial Services, LLC | 3.8% | ||
|
Morgan Stanley
13G/A
Amendment 6
|
7.9% |
11/7/2025
Event 9/30/2025
|
|
| Morgan Stanley | 7.9% | ||
| Morgan Stanley Investment Management Inc. | 7.9% | ||
| Morgan Stanley Institutional Fund, Inc. International Advantage Portfolio | 6.0% | ||
|
Patient Capital Management, LLC
13G/A
Amendment 3
|
1.6% |
8/14/2025
Event 6/30/2025
|
|
| Patient Capital Management, LLC | 1.6% | ||
| Patient Opportunity Trust, a series of Advisor Managed Portfolios | 0.7% | ||
|
Ameriprise Financial, Inc.
13G/A
Amendment 4
|
5.1% |
8/14/2025
Event 6/30/2025
|
|
| Ameriprise Financial, Inc. | 5.1% | ||
| Ameriprise Financial Services, LLC | 5.1% | ||
|
FMR LLC
13G/A
Amendment 7
|
9.8% |
8/6/2025
Event 6/30/2025
|
|
| FMR LLC | 9.8% | ||
| Abigail P. Johnson | 9.8% | ||
| Massachusetts Financial Services Co /MA/ 13G/A Amendment 2 | 4.0% |
5/14/2025
Event 3/31/2025
|
|
|
Patient Capital Management, LLC
13G/A
Amendment 2
|
5.8% |
4/24/2025
Event 3/31/2025
|
|
| Patient Capital Management, LLC | 5.8% | ||
| Patient Opportunity Trust, a series of Advisor Managed Portfolios | 4.2% | ||
|
Bain Capital Integral Investors 2008, L.P.
13G/A
Amendment 5
|
30.5% |
2/14/2025
Event 12/31/2024
|
|
| Bain Capital Integral Investors 2008, L.P. | 19.0% | ||
| BCPE Fund X Goose Holdings, L.P. | 30.5% | ||
|
Patient Capital Management, LLC
13G/A
Amendment 1
|
8.4% |
2/12/2025
Event 12/31/2024
|
|
| Patient Capital Management, LLC | 8.4% | ||
| Patient Opportunity Trust, a series of Advisor Managed Portfolios | 6.3% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 30.4 k | $237 k |
| 2026 Q2 | 122 | 24.5 M | $233 M |
| 2026 Q1 | 124 | 28.1 M | $308 M |
| 2025 Q4 | 161 | 28.8 M | $373 M |
| 2025 Q3 | 149 | 28.5 M | $393 M |
| 2025 Q2 | 140 | 32.6 M | $365 M |
| 2025 Q1 | 124 | 30.9 M | $246 M |
| 2024 Q4 | 139 | 33.5 M | $336 M |
| 2024 Q3 | 153 | 36.7 M | $459 M |
| 2024 Q2 | 144 | 45.4 M | $600 M |
| 2024 Q1 | 158 | 52.4 M | $632 M |
| 2023 Q4 | 154 | 53.3 M | $633 M |
| 2023 Q3 | 144 | 51.6 M | $757 M |
| 2023 Q2 | 155 | 52.4 M | $934 M |
| 2023 Q1 | 169 | 57.2 M | $1.10 B |
| 2022 Q4 | 170 | 49.9 M | $889 M |
| 2022 Q3 | 161 | 45.7 M | $700 M |
| 2022 Q2 | 166 | 47.0 M | $848 M |
| 2022 Q1 | 167 | 50.0 M | $1.32 B |
| 2021 Q4 | 190 | 45.8 M | $1.70 B |
| 2021 Q3 | 170 | 47.7 M | $1.72 B |
| 2021 Q2 | 180 | 49.9 M | $2.19 B |
| 2021 Q1 | 190 | 50.0 M | $1.98 B |
| 2020 Q4 | 201 | 56.8 M | $1.70 B |
| 2020 Q3 | 190 | 52.9 M | $1.71 B |
| 2020 Q2 | 172 | 52.4 M | $1.22 B |
| 2020 Q1 | 186 | 55.1 M | $1.10 B |
| 2019 Q4 | 220 | 63.2 M | $2.28 B |
| 2019 Q3 | 213 | 62.9 M | $2.76 B |
| 2019 Q2 | 237 | 58.7 M | $2.28 B |
| 2019 Q1 | 275 | 57.0 M | $2.74 B |
| 2018 Q4 | 242 | 54.2 M | $2.38 B |
| 2018 Q3 | 203 | 42.4 M | $2.74 B |
| 2018 Q2 | 201 | 42.8 M | $2.52 B |
| 2018 Q1 | 156 | 33.1 M | $1.11 B |
| 2017 Q4 | 157 | 30.3 M | $957 M |
| 2017 Q3 | 124 | 29.4 M | $604 M |
| 2017 Q2 | 135 | 29.2 M | $577 M |
| 2017 Q1 | 79 | 15.9 M | $253 M |
| 2016 Q1 | 1 | 431 | $21.0 k |